Le Lézard
Classified in: Health
Subjects: HEALTH, GOVERNMENT CONTRACTS

CCSA and Health Canada Invest $1.8 Million in Cannabis Research Projects


OTTAWA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- It has been more than two years since Canada became the first G20 country to legalize recreational cannabis and cannabis products. The Canadian Centre on Substance Use and Addiction (CCSA) is investing $1.8 million dollars in research on non-therapeutic cannabis and the impacts of its legalization on public health and safety throughout the country. Through financial support from Health Canada, CCSA is funding 19 projects on subjects ranging from cannabis legalization and mental health to a comparison of legal versus illicit cannabis sales.

All levels of government need evidence and information to inform cannabis policy and regulation. The projects chosen for this CCSA initiative also include research on specific populations such as Indigenous peoples, veterans, and pregnant and breastfeeding mothers.

Each project will receive funding of up to $100,000 over two years. The Mental Health Commission of Canada is contributing $100,000 to support awarded projects with a mental health focus for a combined research investment of $1.8 million.

"These projects are an opportunity to significantly increase our understanding of cannabis in Canada today. They explore so many different topics: from product labelling regulations to the risks and potential benefits of CBD and THC to cannabis' effect on mental health. The evidence generated from this research will inform and help evaluate the impacts cannabis regulation has had since the Cannabis Act was passed in 2018," explained Rita Notarandrea, CEO of CCSA.

Following a call for proposals last year to explore areas in cannabis policy and research, CCSA awarded funding to the successful applicants through an independent review panel and rigorous peer-reviewed scoring process.

As part of this initiative, CCSA created the Canadian Cannabis Research Database, an online tool capturing current and ongoing cannabis research activities in Canada. CCSA has also created an interactive policy map to support researchers and the public with up-to-date information on the different provincial and territorial regulations and bylaws.

Please see the list of successful proposals and project summaries.

Media contact

Wendy Schlachta, Communications Advisor, Canadian Centre on Substance Use and Addiction
Tel.: 1-833-235-4048, extension 285  I  Email: [email protected]  I  Twitter: @CCSAcanada

CCSA was created by Parliament to provide national leadership to address substance use in Canada. A trusted counsel, we provide national guidance to decision makers by harnessing the power of research, curating knowledge and bringing together diverse perspectives.

CCSA activities and products are made possible through a financial contribution from Health Canada. The views of CCSA do not necessarily represent the views of the Government of Canada.


These press releases may also interest you

at 09:13
Methodist Le Bonheur Healthcare announced Methodist University Hospital earned top recognition by Money magazine as one of the Best U.S. Hospitals for Cardiac Care. The Memphis-based healthcare system's academic flagship landed 15th out of 75 and is...

at 09:06
Avicenna.AI, a leading medical imaging AI company, has received Medical Device Regulation (MDR) certificate for five of its algorithms from certification body BSI Medical Devices. This development means the company's product portfolio is fully...

at 09:03
Insmed Incorporated , a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that additional positive results from the ASPEN...

at 09:00
In March 2024, dairy cows in Texas were found to be infected with highly pathogenic avian flu, or H5N1 bird flu, in the first known case of the virus spreading to cattle. Since then, H5N1 has been found in about 200 animals?and 3 people?across 12...

at 09:00
Emmaus Life Sciences, Inc. , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2023....

at 09:00
Global health company The Cigna Group will release its second quarter 2024 financial results on Thursday, August 1, 2024, and will host a conference call the same day....



News published on and distributed by: